Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847990 · ClinicalTrials.gov registry record
Non-Invasive Screening for Fetal Aneuploidy
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 5,000
- Enrollment target
NCT00847990: Completed study, sponsored by Sequenom.
NCT00847990 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 5,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00847990 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 5,000 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or other chromosome abnormality.
Interventions
- OTHER Maternal blood screening test for fetal aneuploidy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-08 |
What the finished NCT00847990 record still lists
NCT00847990 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Maternal blood screening test for fetal aneuploidy is the first listed.
NCT00847990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00847990 about?
NCT00847990 is a clinical study titled "Non-Invasive Screening for Fetal Aneuploidy". The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards...
What is the current status of trial NCT00847990?
This trial is currently completed. The enrollment target is 5,000 participants. The study started on 2009-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00847990?
The interventions under investigation include: Maternal blood screening test for fetal aneuploidy (OTHER).
Who is sponsoring clinical trial NCT00847990?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia